Devices for intradermal vaccination

Kis, Elsa E.; Winter, Gerhard; Myschik, Julia

doi:10.1016/j.vaccine.2011.11.020

Cited by 94 publications

(45 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[24][25][26] A few such delivery devices exist, such as the liquid jet injector and the intradermal microinjection system. 27 New technology that enhances immunity to vaccines is necessary to improve their clinical efficacy and effectiveness and to reduce influenza-related morbidity and mortality further. Additional investigations and new innovations to optimize immunization are necessary.…”

Section: Discussionmentioning

confidence: 99%

Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan

Hata

Mano

Nakamura

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Immunization of health care personnel (HCP) is critically important to reduce healthcare-associated influenza infections substantially. During 2009During -2010 of all HCP at Kitano Hospital, Osaka, Japan, including 94% of pediatricians, received the monovalent unadjuvanted influenza A (H1N1) pdm09 vaccine.We evaluated the vaccine's immunogenicity. Sixteen pediatricians received 15 mg hemagglutinin antigen subcutaneously. Antibody titer assays were conducted using hemagglutination-inhibition antibody assay on days 0 and 21 and at 5 mo after vaccination. Seroprotection rates, seroconversion rates, and geometric mean titer folds at 21 d were, respectively, 43.8%, 43.8% and 5.4 in all subjects, 70.0%, 70.0% and 8.0 in subjects aged 27-34 y, and 0.0%, 0.0% and 8.0 in subjects aged $ 35 y. None of the latter group met the European Medicines Agency criteria.We hope to adopt intradermal routes and further the development of the influenza vaccine using new technology to improve immunogenicity in Japan.

show abstract

Section: Discussionmentioning

confidence: 99%

Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan

Hata

Mano

Nakamura

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…One such example for vaccines delivery is reported by Edmonston-Zagreb for measles vaccination (Nordquist et al, 2007;Herwadkar & Banga, 2012;Kis et al, 2012;Singh et al, 2012;Edens et al, 2013;Koutsonanos et al, 2013;Ling & Chen, 2013;Cai et al, 2014;Gill et al, 2014). Vaccinations have the capacity to be delivered using MN patches, which require the patient to have no specialized training or the need for cold/refrigerated storage; this in turn can reduce the spread of diseases Edens et al, 2013).…”

Section: Why Mns?mentioning

confidence: 99%

Microneedles for drug delivery: trends and progress

2014

View full text Add to dashboard Cite

In recent years, there has been a surge in the research and development of microneedles (MNs), a transdermal delivery system that combines the technology of transdermal patches and hypodermic needles. The needles are in the hundreds of micron length range and therefore allow relatively little or no pain. For example, biodegradable MNs have been researched in the literature and have several advantages compared with solid or hollow MNs, as they produce non-sharp waste and can be designed to allow rapid or slow release of drugs. However, they also pose a disadvantage as successful insertion into the stratum corneum layer of the skin relies on sufficient mechanical strength of the biodegradable material. This review looks at the various technologies developed in MN research and shows the rapidly growing numbers of research papers and patent publications since the first invention of MNs (using time series statistical analysis). This provides the research and industry communities a valuable synopsis of the trends and progress being made in this field.

show abstract

“…22,23 Although preliminary results of ID vaccination against influenza are promising and have demonstrated good immunogenicity with lower antigen doses compared with IM administration, [24][25][26][27] the traditional ID technique for vaccine delivery (the Mantoux technique) is not easy to perform correctly and requires trained personnel and fine maneuvering of a needle into a 1-2 mm deep layer of tissue. 28 To overcome these limitations, new ID injection devices have been developed to deliver vaccine more reliably and conveniently, which employ short needles (1.5 mm in length), 14,[29][30][31][32] and microneedles (<1.0 mm in length). [32][33][34][35] MicronJet ® (NanoPass Technologies) is one such novel device using microneedles.…”

Section: Mf59mentioning

confidence: 99%

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration

Cioppa

Nicolay

Lindert

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Strategies to optimize responses to seasonal influenza vaccination in older adults include the use of adjuvants, higher antigen doses, and intradermal delivery. In this study adults aged >= 65 years (n = 450) received a single dose of 1 of 2 non-adjuvanted trivalent influenza vaccine (TIV) formulations administered intradermally (ID), both containing 6 mu g of A/H1N1 and B, differing in A/H3N2 content (6 mu g or 12 mu g), or a single dose of 1 of 8 TIV formulations administered intramuscularly (IM) all containing 15 mu g of A/H1N1 and B, differing in A/H3N2 hemagglutinin (HA) content (15 mu g or 30 mu g) and/or in MF59 (R) adjuvant content (0%, 25%, 50%, or 100% of the standard dose). This paper focuses on the comparisons of low-dose non-adjuvanted ID, full-dose non-adjuvanted IM and full-dose MF59-adjuvanted IM formulations (n = 270). At day 22 post-vaccination, at least one European licensure immunogenicity criterion was met by all groups against all 3 strains; however, all three criteria were met against all 3 vaccine strains by the low-dose non-adjuvanted ID and the full-dose MF59-adjuvanted IM groups only. The full-dose MF59-adjuvanted IM group elicited significantly higher immune response vs. the low-dose non-adjuvanted ID formulations for most comparisons. The full-dose MF59 adjuvanted IM groups were associated with increased pain at the site of injection (P < 0.01) compared to the ID groups, and the low-dose non-adjuvanted ID groups were associated with increased erythema, induration, and swelling at the injection site (P < 0.0001) and unsolicited AEs compared with the IM groups. There were no differences between IM and ID groups in the frequencies of subjects experiencing solicited systemic reactions. Overall, while MF59 adjuvantation increased pain at the site of injection, and intradermal delivery increased unsolicited adverse events, erythema, induration, and swelling at the injection site, both strategies of vaccination strongly enhanced the immunogenicity of seasonal influenza vaccine in older adults compared with conventional non-adjuvanted intramuscular delivery

show abstract

Devices for intradermal vaccination

Cited by 94 publications

References 187 publications

Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan

Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan

Microneedles for drug delivery: trends and progress

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration

Contact Info

Product

Resources

About